Advances in tumor immunotherapy and gene therapy

Abstract

<p indent="0mm">As emerging tumor immunotherapy and gene therapy products such as immune checkpoint inhibitors, oncolytic viruses and chimeric antigen receptor T (CAR-T) cells approved for clinical use, tumor immunotherapy and gene therapy have revolutionized the treatment of some solid tumors and blood tumors. On a global scale to obtain authoritative organization and leading experts of broad consensus, tumor immunotherapy and gene therapy are becoming the first-line treatment for a wide variety of tumor treatment. However, this field is still facing some questions to be solved, including the immunotherapy-related adverse reactions and the non-significant efficacy of oncolytic virus, and CAR-T cells should break through the treatment of solid tumors and reduce the expensive price. Aiming at these key scientific issues, the research teams from West China Hospital of Sichuan University have made a series of achievements from disease molecular network to drug discovery, development and translation based on innovative biotechnology. Herein, this paper briefly reviews the progress of tumor immunotherapy and gene therapy in recent years from West China Hospital of Sichuan University. We look forward to the 130th anniversary of the establishment of West China Hospital as an opportunity to continue to make more world-class achievements and benefit the society in the future.